BioCryst shares tick up on positive results for Ebola-targeted compound

Shares of Research Triangle Park-based drug developer BioCryst Pharmaceuticals shot up more than 10 percent midday Wednesday after the pharma disclosed good news on an antiviral the feds hope could someday offset an Ebola outbreak. Ebola, which made major headlines two years ago when a massive outbreak in West Africa was blamed for thousands of deaths, is a hemorrhagic fever that currently has no FDA-approved vaccine or treatment. According to the Centers for Disease Control and Prevention, IV fluids…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news